Gini Fleming to Carcinoma, Non-Small-Cell Lung
This is a "connection" page, showing publications Gini Fleming has written about Carcinoma, Non-Small-Cell Lung.
Connection Strength
0.030
-
Phase I combination study of the PARP inhibitor veliparib plus carboplatin and gemcitabine in patients with advanced ovarian cancer and other solid malignancies. Gynecol Oncol. 2018 03; 148(3):507-514.
Score: 0.020
-
Pharmacogenomic and pharmacokinetic determinants of erlotinib toxicity. J Clin Oncol. 2008 Mar 01; 26(7):1119-27.
Score: 0.010